APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial
Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
March 12, 2021
No Comments
Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution to people’s #wellbeing by developing the immune therapy APN401. APN401´s proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid...
February 4, 2021
No Comments
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)
December 4, 2020
No Comments
APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020
No Comments
APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor
British investor consortium Franklin Road Ltd. increases its stake in APEIRON Biologics significantly to over 13% Extraordinary General Meeting elects Edward Charles MA, Managing Director of Franklin Road Ltd., as a new Supervisory Board member Press release (EN) | Presseaussendung (DE)
October 15, 2020
No Comments
THE LANCET publishes promising data of APEIRON’s APN01 (rhsACE2) to treat COVID-19 in named patient use
Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial First data on the effect of blocking the spike protein in COVID-19 patient confirm mode of action of APN01 specifically targeting SARS-CoV-2 Press release (EN) | Presseaussendung (DE)
September 25, 2020
No Comments
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials. Press release (EN) | Presseaussendung (DE)
July 8, 2020
No Comments
APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. Expansion of the ongoing phase II clinical trial to USA and Russia planned.
APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. Expansion of the ongoing phase II clinical trial to USA and Russia planned. Press release (EN) |...
June 3, 2020
No Comments